Celcuity Inc. 8-K Summary: Term Loan Closing
Business Context and Reporting Period
Celcuity Inc. (CELC), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on December 22, 2022. The filing reports the closing of a new term loan facility on the same date, following a $100 million private placement completed on December 9, 2022.
Key Financial Metrics and Debt Obligations
This filing details a specific debt transaction rather than comprehensive financial performance metrics such as revenue or operating cash flow.
- New Debt: $20.0 million Term B Loan closed on December 22, 2022.
- Lender: Innovatus Life Sciences Lending Fund I, L.P.
- Total Facility Capacity: Up to $75.0 million across five term loans.
- Interest Rate: Greater of Prime Rate or 3.25%, plus 5.70%.
- Payment Structure: Interest-only payments permitted until May 1, 2025 (potentially extendable to May 1, 2026). The Company elected to pay 4.95% of the interest rate in-kind (PIK), accruing as additional principal.
- Maturity Date: April 8, 2027.
- Collateral: Secured by all assets of the Company.
Material Changes and Loan Terms
The closing of the Term B Loan represents a material increase in the Company's debt obligations and liquidity position. Key terms include:
- Prepayment: Optional prepayment allowed after August 9, 2023, with tiered fees ranging from 0.00% to 1.00%. Mandatory prepayment is required upon a change of control or event of default.
- Final Fee: A 4.5% fee on funded amounts not converted to equity applies if prepayment, default, or change of control occurs before August 9, 2025.
- Conversion Rights: The lender may convert up to $6.6 million of outstanding principal into common stock at a price of $10.00 per share until August 9, 2025. This includes 20% of the initial term loan and 7% of funded amounts exceeding $35 million.
- Covenants: The agreement includes financial covenants based on liquidity, trailing twelve-month revenue, and funded loan amounts.
Guidance, Outlook, and Risks
Proceeds from the loan are designated for working capital and general business requirements. The filing does not provide updated revenue guidance or specific management commentary on future operational outlook beyond the use of proceeds.
Risks and Contingencies:
- Default Acceleration: The lender may accelerate the debt upon customary events of default, including failure to make payments or breach of financial covenants.
- Dilution Risk: The conversion rights could result in the issuance of additional shares, subject to the $10.00 per share conversion price.
- Liquidity Covenants: The Company must maintain specific liquidity and revenue thresholds to avoid default.
Investor Verification Checklist
- Verify the Company's current liquidity position to ensure compliance with the new financial covenants.
- Review the impact of the 4.95% PIK interest on the total principal balance over time.
- Assess the potential dilution impact if the lender exercises conversion rights on up to $6.6 million of principal.
- Confirm the status of the remaining $55.0 million capacity under the Amended Loan Agreement.
- Monitor the Company's ability to meet the interest-only payment schedule and eventual principal repayment in 2027.